Tividenofusp Alfa-eknm (Avlayah; Denali Therapeutics Inc.) for Mucopolysaccharidosis Type II (Hunter Syndrome)

A hydrolytic lysosomal glycosaminoglycan-specific enzyme indicated for the treatment of neurologic manifestations of Hunter syndrome in presymptomatic or symptomatic pediatric patients prior to advanced neurologic impairment.